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Summary
Objective: To investigate osteopontin (OPN) levels in both synovial ﬂuid and articular cartilage of patients with primary knee osteoarthritis (OA)
and their relationship with severity of the disease.
Method: Fifty patients aged 48e81 years with knee OA and 10 healthy controls were enrolled in this study. Anteroposterior knee radiographs
or/and Mankin score were taken to determine the disease severity of the affected knee. The radiographic grading of OA in the knee was
performed by using the Kellgren-Lawrence criteria. OPN levels in synovial ﬂuid were measured using enzyme-linked immunosorbent assay.
OPN levels in articular cartilage were assessed by immunohistochemical methods.
Results: Compared to healthy controls, OA patients had higher OPN concentration in synovial ﬂuid (4519.60 1830.37, 95%CI
3999.42e5039.79 vs 1179.70 303.39, 95%CI 1035.53e1438.74 pg/ml, P< 0.001)and articular cartilage(0.6 0.06, 95%CI 0.59e0.62 vs
0.43 0.07, 95%CI 0.38e0.48, P< 0.01). In addition, synovial ﬂuid OPN levels showed a positive correlation with articular cartilage OPN
levels (r¼ 0.411, 95%CI 0.150e0.619, P¼ 0.003). Subsequent analysis showed that synovial ﬂuid OPN levels signiﬁcantly correlated with
severity of disease (Spearman’s r¼ 0.581, 95%CI 0.335e0.726, P< 0.001). Furthermore, the articular cartilage levels of OPN also correlated
with disease severity (Spearman’s r¼ 0.675, 95%CI 0.500e0.808, P< 0.001).
Conclusions: OPN in synovial ﬂuid and articular cartilage is associated with progressive joint damage and is likely to be a useful biomarker for
determining disease severity and progression in knee OA.
Crown Copyright ª 2009 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International. All rights reserved.
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Osteoarthritis (OA), the most prevalent joint disease, is
characterized by the progressive loss of articular cartilage
that leads to chronic pain and functional restrictions in
affected joints. Worldwide estimates are that about 10% of
men and 18% of women and about 60e65% aged over
60 years have symptomatic OA and 80% of those have
limitations in movement. The clinical features of OA include
pain, stiffness, reduced motion, swelling, crepitus and
deformity. Although clinical research on OA has been ex-
tensively investigated, the etiology of this disease remains
poorly elucidated. Several biochemical and biomechanical
factors are considered for the pathogenesis.
OPN (osteopontin) is a 44w75 KD multifunctional phos-
phoprotein secreted by many cell types such as osteo-
clasts, macrophages, lymphocytes, epithelial cells andaThese authors contributed equally to this paper.
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82vascular smooth muscle cells (SMC)1,2 and is present in
the extracellular matrix of mineralized tissues and in extra-
cellular ﬂuids, at sites of inﬂammation3,4. Gene structure
and chromosomal location identify OPN as a member of
the small integrin-binding ligand N-linked glycoprotein (SIB-
LING) family. This protein also known as early T cell activa-
tion gene-1 (Eta-1) is abundant in bone, where it mediates
important cell-matrix and cell-cell interactions5.OPN expres-
sion during chondrocyte maturation is one of the important
events involved in cartilage-to-bone transitions in fracture
repair6,7. OPN facilitates the attachment of osteoclasts to
the bone matrix via an interaction with cell surface avb3
integrin and CD44, the hyaluronic acid receptor6,8e10.
OPN may be involved in the molecular pathogenesis of
OA, contributing to progressive degeneration of articular
cartilage11. Expression of OPN mRNA isolated from human
OA cartilage was enhanced as compared with normal carti-
lage. OPN was shown to be upregulated in human OA
chondrocytes12. Moreover, OPN was found to be ex-
pressed in bone forming cells and hypertrophic chondro-
cytes of the embryonic epiphyseal growth plates13.
It has been reported that OPN was present in plasma and
synovial ﬂuid of patients with rheumatoid arthritis and with
OA6, There have been no detailed studies on synovial ﬂuid
83Osteoarthritis and Cartilage Vol. 18, No. 1and articular cartilage levels of OPN in various clinical
stages of primary knee OA14e19. The relationship between
OPN levels in the synovial ﬂuid and OPN expression in ar-
ticular cartilage and disease severity has never been previ-
ously reported in the literature. We hypothesized that OPN
in synovial ﬂuid and articular cartilage may be associated
with the severity of clinical outcomes in knee OA patients.
To prove this hypothesis we examine the synovial ﬂuid
and articular cartilage levels of OPN in knee OA patients
and healthy controls.
The purpose of the present study was to investigate the
concentrations of OPN in both synovial ﬂuid and articular
cartilage of patients with primary knee OA, and evaluate
the possible correlations with the radiographic grading
and Mankin score of knee OA, which may serve as a useful
tool to mark the osteoarthritic disease process and to further
elucidate the pathways involved in the progression of the
disease.MethodsPATIENTS AND PREPARATION OF SAMPLESFifty patients aged 48e81 years with primary knee OA according to the
criteria of the American College of Rheumatology and 10 normal healthy
individuals were enrolled in the study. Clinical data were carefully reviewed
to exclude any forms of secondary OA and inﬂammatory joint diseases
like rheumatoid arthritis. The severity of the disease was determined using
weight-bearing anteroposterior radiographs of the affected knee. Knee radio-
graphs were evaluated according to the Kellgren and Lawrence (KL) classi-
ﬁcation20. Grade 1, doubtful narrowing of joint space and possible
osteophytic lipping. Grade 2, deﬁnite osteophytes and possible narrowing
of joint space. Grade 3, moderate multiple osteophytes, deﬁnite narrowing
of joints space, some sclerosis and possible deformity of bone contour.
Grade 4, large osteophytes, marked narrowing of joint space, severe sclero-
sis and deﬁnite deformity of bone contour. According to the KL grading scale,
13 patients were KL grade 2, whereas 20 patients were KL grade 3 and 17
patients were KL grade 4 OA. The grading scale used for analysis was the
higher of the two knees.
Fifty osteoarthritic cartilage samples were obtained from 50 patients with
primary OA undergoing a total knee replacement. Normal cartilage was col-
lected from 10 human knees at the time of autopsy, within 18 h after death
(37-58-year-old donors). Osteoarthritic changes were classiﬁed histomor-
phologically, using the grading system of Mankin21. Mankin score 0: Normal
cartilage with a smooth surface and a regular zonal distribution of the chon-
drocytes. Mankin score 1e4: Cartilage surface shows ﬁbrillations and
a superﬁcial loss of proteoglycans(safranin-O staining), the zonal structure
is intact. Mankin score 5e8: Cartilage samples have clefts reaching down
to the middle cartilage zone, clusters of proliferating chondrocytes are pres-
ent. Mankin score 9: Severely affected cartilage samples, clefts are reach-
ing down to the deep zone, the tangential zone is lost and chondrocyte
clusters are present. Ten samples (Mankin score 0), 13 samples (Mankin
score 1e4), 19 samples (Mankin score 5e8) and 18 samples (Mankin score
9) were included in this study.ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)Synovial ﬂuid was aspirated from the affected knee during surgery, when
a total knee arthroplasty was performed, centrifuged to remove cells and joint
debris and stored immediately at 70C until the day of measurement. Dou-
ble-blined quantitative detection of OPN in synovial ﬂuid was performed
using commercial ELISA (Uscnlife Science & Technology Company, China)
according to the manufacturers’ instructions. Brieﬂy, standards of recombi-
nant human OPN and synovial ﬂuid samples were added to 96-well microtiter
plates precoated with rabbit polyclonal antibody against OPN and incubated
for 1 h at room temperature. The wells were then washed seven times with
washing buffer and incubated for 30 min at 4C with a horseradish peroxi-
dase-labeled mouse monoclonal antibody to human OPN. After nine
washes, substrate solution was added to each well and the plate was incu-
bated for 30 min at room temperature in the dark. Finally, the reaction was
stopped with the stop solution and then absorbance was measured at
450 nm using automated microtiter plate reader. The OPN concentration
was calculated by the standard curve. Twofold serial dilutions of recombinant
human OPN with a concentration of 156e10,000 pg/ml were used as stan-
dards. Each data was evaluated by three independent experiments. The
assays had intra-assay coefﬁcients of variation <5% and inter-assay coefﬁ-
cients of variation <6%.IMMUNOHISTOCHEMISTRYBiopsies (cartilager/bone samples) were cut from both lateral and medial
sides of tibia plateau including the loading zone, as well as the margin zone
whenever possible. Cartilager/bone samples (1.0 cm thick) with a cartilage
surface of approximately 2.0 0.5 cm were incubated in freshly prepared
paraformaldehyde, then dehydrated in a grading concentration of ethanol
and xylene and ﬁnally embedded in parafﬁn. Representative formalin-ﬁxed,
parafﬁn-embedded tissue blocks were retrieved and sectioned for the immu-
nohistochemical study. The sections were deparafﬁnized, treated with 3%
hydrogen peroxide for 10 min and then microwaved in 10 mM citrate buffer
(pH 6.0) to unmask the epitopes. The sections were then incubated with
diluted OPN antibody (AKm2A1, 1:100) for 1 h. After wash, horseradish per-
oxidase/Fab polymer conjugate (PicTureTM-Plus kit, Zymed, South San
Francisco, CA) was applied to the sections for 30 min. Finally, the sections
were incubated with diaminobenzidine for 5 min to develop the signals.
A negative control was simultaneously performed by omitting the primary
antibody. All the sections were evaluated by a pathologist who was unaware
of the clinical data. To evaluate the expression of OPN, the sections were
examined under a microscope at 100 magniﬁcation. Positive OPN immu-
nostaining was deﬁned as detectable immunoreactivity in the perinuclear
and/or other cytoplasmic regions in chondrocytes. The relative OPN distribu-
tion of cartilage tissue can be visualized and quantiﬁed as optical density
(OD). Semiquantitative assessment of mean OD of OPN expression was
performed on scanned auto-radiograms using MIAS-4400 Image J. Gray-
scale images were captured and converted to absorbance units and a region
from the cartilage surface to the cartilage-bone junction was analyzed. All
densities were normalized to phosphate-buffered saline (PBS). The experi-
ment was repeated for three times. To reduce the error arising from the
slightly varying section thickness, a total of three sections per sample were
measured and averaged. The ﬁnal data, which were applied in all analysis,
consisted therefore of a mean of three independent measurements repre-
senting the average levels of OPN in articular cartilage. The coefﬁcient of
variation (CV) of OPN expression in articular cartilage was <2%.Statistical analysis
SPSS for Windows (version 13.0) was used for data man-
agement and statistical analysis. Tests of normality and test
of homogeneity of variances were performed to analyze the
subject’s age, body mass index, concentration of OPN in
the synovial ﬂuid and the articular cartilage OPN expres-
sion. The analysis of co-variance (ANCOVA) indicated
that age, sex and body mass index were not potential con-
founding factors in this study. When the populations from
which the samples were normally or approximate normal
distribution and the variances of the populations were
equal, Student’s t-test was employed to compare the means
of two independent groups and one way analysis of vari-
ance (ANOVA) was employed to compare the means of
more than two independent groups. Comparisons between
groups were made using ManneWhitney U test (for two
groups) or KruskaleWallis test (for more than two groups)
when the variances were not equal among the groups.
Spearman’s correlation was employed to determine the cor-
relation between synovial ﬂuid levels of OPN and severity of
OA. Spearman’s correlation and linear regression were
used to determine the correlation between OD of OPN in
articular cartilage and Mankin score of OA. Pearson’s corre-
lation and linear regression were applied to determine the
correlation between synovial ﬂuid OPN levels and OD of
OPN in articular cartilage. Spearman’s correlation coefﬁ-
cients and Pearson’s correlation coefﬁcients were calcu-
lated using Prism 5.0 software (GraphPad, Inc., San
Diego, CA). Data were expressed as mean standard de-
viation (SD). A P-value less than 0.05 was taken as statis-
tically signiﬁcant.Results
A total of 60 knees were analyzed from 50 patients (35
female) and 10 controls (6 female). Characteristics of the
Table I
Characteristics of patients (n¼ 50) and controls (n¼ 10)
Osteoarthritis patients Controls P
Age (years) 61.8 7.4, 95%CI: 59.6e63.9 63.2 6.0, 95%CI: 58.9e67.5 0.57
Gender (%female) 70% 60% 0.54
BMI (kg/m2) 27.08 0.44, 95%CI: 26.96e27.20 26.82 0.44, 95%CI: 26.50e27.14 0.09
*BMI¼ body mass index.
10000
84 S. G. Gao et al.: OPN is associated with disease severity in OAstudy population are shown in Table I. There was no clinical
meaningful difference in age between OA patients
(61.8 7.4, 95%CI 59.6e63.9) and controls (63.2 6.0,
95%CI 58.9e67.5, P¼ 0.57). There was no difference
between OA patients and controls for sex (70% vs 60%
females, Chi-square P¼ 0.54) and body mass index
(27.08 0.44, 95%CI 26.96e27.20 vs 26.82 0.44,
95%CI 26.50e27.14 kg/m2, P¼ 0.09).
Synovial ﬂuid OPN levels of knee OA patients and con-
trols are demonstrated in Fig. 1. OA patients had higher
synovial ﬂuid OPN concentrations compared to healthy
controls (4519.60 1830.37, 95%CI 3999.42e5039.79 vs
1179.70 303.39, 95%CI 1035.53e1438.74 pg/ml,
P< 0.001). The synovial ﬂuid levels of OPN were analyzed
and compared in relation to radiological KL grading of OA.
The synovial ﬂuid levels of OPN from KL grade 2 were
3543.82 811.19 (95%CI 2817.71e4269.93) pg/ml, those
from KL grade 3 were 4013.63 676.81 (95%CI
3228.86e4798.91) pg/ml and those from KL grade 4 were
6170.01 773.50 (95%CI 3999.42e5039.79) pg/ml. The
data revealed that synovial ﬂuid OPN levels in KL grade 4
were signiﬁcantly elevated compared with those of KL
grade 2 and 3 (P< 0.01). The synovial ﬂuid levels of OPN
also correlated with disease severity (Spearman’s
r¼ 0.581, 95%CI 0.335e0.726, P< 0.001) (Fig. 2). In order
to compare synovial ﬂuid levels of OPN as a function of age
among OA patients, they were categorized into three age
groups as follows: less than 60 years of age, 60e75 years
of age and more than 75 years of age. There was no statis-
tically signiﬁcant difference in synovial ﬂuid OPN levels
among patients with OA (P¼ 0.15).
In the normal cartilagerbone section (Mankin score 0),
OPN expression wasn’t found in all nucleated cellscontro
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Fig. 1. Synovial ﬂuid levels of OPN in healthy controls (n¼ 10),
osteoarthritis patients (n¼ 50) and osteoarthritis patients from KL
grade 2 (n¼ 13), KL grade 3 (n¼ 20) and KL grade 4 (n¼ 17).
* P< 0.001 vs controls; # P< 0.01 vs KL grade 2 OA and KL grade
3 OA.(Fig. 3). In the cartilagerbone section (Mankin score 1e4),
a faint staining was visible in the territorial matrix surround-
ing deep zone chondrocytes (Fig. 3). In cartilage samples
with a Mankin score of 5e8, the staining was more pro-
nounced in deep zone chondrocytes and their surrounding
matrix (Fig. 3). Sections with severe osteoarthritic (Mankin
score 9), the strongest OPN expression was detected in
these samples. Clusters of chondrocytes and chondrocytes
from the deep cartilage zone showed cellular and extracel-
lular OPN deposition. Osteocytes and bone trabeculae lin-
ing cells stained positive for OPN (Fig. 3). Average OD of
OPN in articular cartilage of OA patients and healthy con-
trols was 0.6 0.06 (95%CI 0.59e0.62) and 0.43 0.07
(95%CI 0.38e0.48) respectively. OA patients had higher
articular cartilage OPN expression compared to healthy
controls (P< 0.01). The articular cartilage OPN expression
correlated with Mankin score (Spearman’s r¼ 0.675,
95%CI 0.500e0.808, P< 0.001, regression equation:
by ¼ 15:442þ 37:772x ; F¼ 42.055, P< 0.001, b 95%CI
26.061e49.483) (Fig. 4). Interestingly, synovial ﬂuid OPN
levels showed a positive correlation with articular
cartilage OPN expression (Pearson’s r¼ 0.411, 95%CI
0.150e0.619, P¼ 0.003, regression equation: by ¼ 0:541þ
1:33  105x ; F¼ 9.775, P< 0.001, b 95%CI 0.47*105
e2.18*105) (Fig. 5).Discussion
This study revealed a marked increase of OPN levels in
both synovial ﬂuid and articular cartilage of patients withKL grade of OA
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Fig. 2. Synovial ﬂuid levels of OPN correlated with KL grade of
osteoarthritis (Spearman’s r ¼ 0.581, 95%CI 0.335e0.726,
P< 0.001). The severity of the disease was determined using
weight-bearing anteroposterior radiographs of the affected knee.
Knee radiographs were evaluated according to the KL classiﬁca-
tion. Spearman’s correlation was employed to determine the corre-
lation between synovial ﬂuid levels of OPN and severity of
osteoarthritis.
Fig. 3. OPN immunohistochemical staining in articular cartilage of knee osteoarthritis patients and controls. (a) OPN expression wasn’t found
in the perinuclear and/or other cytoplasmic regions in chondrocytes of controls. (b) The faint staining was visible in the territorial matrix sur-
rounding deep zone chondrocytes of minor osteoarthritis patients with a Mankin score of 1e4. (c) The staining was more pronounced in deep
zone chondrocytes and their surrounding matrix of moderate osteoarthritis patients with a Mankin score of 5e8. (d) The strongest OPN stained
in chondrocytes, chondrocytes from the deep cartilage zone, chondrocytes surrounding matrix and bone trabeculae lining cells of severe os-
teoarthritis patients (Mankin score 9).
85Osteoarthritis and Cartilage Vol. 18, No. 1kneeOA compared with the controls. Elevated levels of OPN
in synovial ﬂuid are possibly caused by either the release of
OPN residing in extracellular matrix, or the increase in its pro-
duction, or both processes. The source of the OPN in the
synovial ﬂuid is presumably to be the local tissues, such asoptical density of OPN in articular cartilage
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Fig. 4. OD of OPN in articular cartilage correlated with Mankin score
of osteoarthritis (Spearman’s r ¼ 0.675, 95%CI 0.500e0.808,
P < 0 .001 , r eg ress i on equa t i on : by ¼ 15:442þ 37:772x ;
F¼ 42.055, P< 0.001, b 95%CI 26.061e49.483). Osteoarthritic
changes were classiﬁed histomorphologically, using the grading
system of Mankin. Spearman’s correlation and linear regression
were used to determine the correlation between OD of OPN in
articular cartilage correlated and Mankin score of osteoarthritis.the synovial membrane and articular cartilage. Many studies
had demonstrated the expression of OPN in bone, thus,
bone may also be a source of synovial ﬂuid OPN. When
moderate and severe lesions of the articular cartilage occur,
it can begin to expose subchondral bone in the synovial ﬂuid,synovial fluid osteopontin (pg/ml)
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Fig. 5. Synovial ﬂuid OPN levels correlated with OD of OPN in
articular cartilage (Pearson’s r ¼ 0.411, 95%CI 0.150e0.619,
P ¼ 0 .003 , r eg ress i on equa t i on : by ¼ 0:541þ 1:33  105x ;
F¼ 9.775, P< 0.001, b 95%CI 0.47*105e2.18*105). Pearson’s
correlation and linear regression were applied to determine the
correlation between synovial ﬂuid OPN levels and OD of OPN in
articular cartilage.
86 S. G. Gao et al.: OPN is associated with disease severity in OAbone may be a source of synovial ﬂuid OPN, but there is not
reported evidence so far to support this hypothesis. Previous
studies have demonstrated the immunohistochemical
expression of OPN in the synovial lining cells17, ﬁbroblasts
in the synovial tissues18 and articular chondrocytes12,18. It
is suggested that cell adhesion, migration or inﬂammation
could be involved in the release of OPN7.
Cartilage damage is one of the main pathological
changes in OA. Synovitis and degenerative changes of
articular cartilage is likely to be facilitating factors in the
release of OPN into the synovial ﬂuid. Interestingly, synovial
ﬂuid OPN levels showed a positive correlation with articular
cartilage OPN expression. Therefore, only by detecting the
levels of OPN in synovial ﬂuid, it may be predictive of the
degree of cartilaginous damage and disease severity. In
accordance with our observations, recent studies have
showed that OPN protein deposition and mRNA expression
increased with morphological signs and the severity of
matrix degradation in human osteoarthritic cartilage12.
These ﬁndings indicate that OPN expression in osteoar-
thritic cartilage strongly correlates with the severity of OA
disease. In addition, Attur et al. have revealed the increased
expression of OPN in human OA cartilage, the expression
of OPN mRNA was highly upregulated as compared with
normal cartilage11. They also found that addition of
recombinant OPN to human OA-affected cartilage under
ex vivo conditions suppressed spontaneous production of
nitric oxide and prostaglandin E2. These ﬁndings suggest
that OPN is overexpressed in OA cartilage and function
as an endogenous inhibitor of production of inﬂammatory
mediators in cartilage. Furthermore, Yaki et al. showed
that the advanced OA cartilage had signiﬁcantly higher
OPN mRNA expression than the minimal OA cartilage22.
The patient matched comparison of minimal and advanced
OA cartilage displayed alterations in gene expression that
may be involved in OA progression.
These results indicate that synovial ﬂuid levels and carti-
lage expression of OPN may play a signiﬁcant role in the
pathogenesis of OA. Previous studies have demonstrated
overexpression of OPN induces proinﬂammatory chemo-
kines and cytokines (e.g., IL-1, IL-8, CXCL1, CCL2, and
so on) and activates nuclear factor-kappa B pathway23.
OPN deﬁciency is consistently shown to prevent the
destruction of joint cartilage and joint swelling through sup-
pression of chondrocyte apoptosis and angiogenesis in the
rheumatoid arthritis model23. This mechanism, mediated by
OPN, is also likely to play a key role in OA. Further investi-
gations are under way in our laboratory to deﬁne the signal-
ing events induced by OPN and potential experimental
strategies for the inhibition of OPN-mediated OA process.
Measurements of synovial levels of OPN could possibly
serve as a biochemical parameter for determining disease
severity and may be predictive of prognosis with respect
to the progression of osteoarthritic disease process. Longi-
tudinal studies may provide further information regarding
the value of OPN as a potential marker to monitor the
course of OA. Additional investigation will be needed to
evaluate the knee radiographs among the control group
because they presumably has no knee pain, but might
have radiographic evidence of OA.
This study has had several limitations. First, the sample
size was not large enough to arrive at deﬁnitive conclu-
sions. Secondly, we investigated only those patients of
knee OA who attended Xiangya Hospital, Central South
University. Thirdly, the cross-sectional design of our study
precluded addressing whether the analyzed level of OPN
predicted alteration in severity in patients with knee OA.The documented normal circulating OPN levels in previ-
ous reports are highly variable, with a range from 31 ng/
ml to 200 ng/ml24e26. In this study, the commercial ELISA
with a concentration of 156e10,000 pg/ml were used for
detecting OPN in human synovial ﬂuid. The exact reason
is unclear but it could be attributed to the different assay
systems and conditions of sample. A critical issue that limits
the applicability of plasma OPN as a speciﬁc marker for OA
is that the OPN level is also increased in a variety of can-
cers. Elevation of circulating OPN levels has been recently
reported in pancreatic cancer, colon cancer, breast cancer,
lung cancer, ovarian cancer, hepatocellular carcinoma and
melanoma27e31. Further investigations with standardized
assay system in a large population are warranted to gain
insight into the potential utility of OPN in OA patients, espe-
cially in synovial ﬂuid.
In summary, patients with primary knee OA had higher
levels of synovial ﬂuid OPN compared with healthy controls.
OPN concentrations in synovial ﬂuid and articular cartilage
signiﬁcantly correlated with the severity of disease. Further
studies are in progress to elucidate the contribution of OPN
to the pathogenesis of the degenerative process of OA.Conﬂict of interest
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